Hugh S Griffith
Chief Executive Officer
T: +44 (0) 131 248 3660
E: info@nucanabiomed.com
W: www.nucanabiomed.com

NuCana to present Phase I clinical data at ASCO 2013 in Chicago on 3rd June 2013

NuCana BioMed ('NuCana') today announced it will be presenting data from the Phase I study (ProGem1) at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO). In addition to impressive pharmacokinetic data and a favourable safety profile, there are clear efficacy signals for patients across a range of solid tumours.

At the meeting, NuCana will present the results for its new anti-cancer medicine NUC-1031 in the "General Poster Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics". The poster, entitled "ProGem1: Phase I first-in-human study of the novel nucleotide analogue, NUC-1031, in adult patients with advanced solid tumors" highlights the safety profile, patient outcomes and pharmacokinetic data from the Phase I study at the Hammersmith Hospital, Imperial College London, UK.

"Our goal is to develop superior anti-cancer agents that will greatly improve patient outcomes," commented Hugh Griffith, CEO of NuCana. "The first of many molecules in our pipeline, ProTide NUC-1031 already shows clear efficacy signals in a patient population with advanced, progressive disease and we are proud to share the results of this important study with the wider community."

About NuCana BioMed

Headquartered in Edinburgh, UK, NuCana BioMed is a clinical stage biopharmaceutical company developing and commercialising a range of exciting, new anti-cancer medicines. With its next generation of anti-cancer agents (nucleotide analogues), NuCana is setting new benchmarks for innovative therapeutic treatments. The state-of-the-art ProTide technology transforms existing therapies into better and safer medicines that overcome key cancer resistance mechanisms.